Literature DB >> 1374166

Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations.

E Arnold1, A Jacobo-Molina, R G Nanni, R L Williams, X Lu, J Ding, A D Clark, A Zhang, A L Ferris, P Clark.   

Abstract

AIDS, caused by human immunodeficiency virus (HIV), is one of the world's most serious health problems, with current protocols being inadequate for either prevention or successful long-term treatment. In retroviruses such as HIV, the enzyme reverse transcriptase copies the single-stranded RNA genome into double-stranded DNA that is then integrated into the chromosomes of infected cells. Reverse transcriptase is the target of the most widely used treatments for AIDS, 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (ddI), but resistant strains of HIV-1 arise in patients after a relatively short time. There are several nonnucleoside inhibitors of HIV-1 reverse transcriptase, but resistance to such agents also develops rapidly. We report here the structure at 7 A resolution of a ternary complex of the HIV-1 reverse transcriptase heterodimer, a monoclonal antibody Fab fragment, and a duplex DNA template-primer. The double-stranded DNA binds in a groove on the surface of the enzyme. The electron density near one end of the DNA matches well with the known structure of the HIV-1 reverse transcriptase RNase H domain. At the opposite end of the DNA, a mercurated derivative of UTP has been localized by difference Fourier methods, allowing tentative identification of the polymerase nucleoside triphosphate binding site. We also determined the structure of the reverse transcriptase/Fab complex in the absence of template-primer to compare the bound and free forms of the enzyme. The presence of DNA correlates with movement of protein electron density in the vicinity of the putative template-primer binding groove. These results have important implications for developing improved inhibitors of reverse transcriptase for the treatment of AIDS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374166     DOI: 10.1038/357085a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  48 in total

1.  Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Tighter binding of HIV reverse transcriptase to RNA-DNA versus DNA-DNA results mostly from interactions in the polymerase domain and requires just a small stretch of RNA-DNA.

Authors:  William P Bohlayer; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2006-06-20       Impact factor: 3.162

3.  Single-particle image reconstruction of a tetramer of HIV integrase bound to DNA.

Authors:  Gang Ren; Kui Gao; Frederic D Bushman; Mark Yeager
Journal:  J Mol Biol       Date:  2006-11-11       Impact factor: 5.469

4.  Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase.

Authors:  Jeffrey J DeStefano; Gauri R Nair
Journal:  Oligonucleotides       Date:  2008-06

Review 5.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

6.  Purification and characterization of an active human immunodeficiency virus type 1 RNase H domain.

Authors:  J S Smith; M J Roth
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Hydroxyl radical footprint analysis of human immunodeficiency virus reverse transcriptase-template.primer complexes.

Authors:  W Metzger; T Hermann; O Schatz; S F Le Grice; H Heumann
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

9.  Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.

Authors:  R Pauwels; K Andries; Z Debyser; P Van Daele; D Schols; P Stoffels; K De Vreese; R Woestenborghs; A M Vandamme; C G Janssen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors.

Authors:  K Rittinger; G Divita; R S Goody
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.